Search

Your search keyword '"Bartalena L"' showing total 1,015 results
Start Over Author "Bartalena L"
1,015 results on '"Bartalena L"'

11. Features and outcome of differentiated thyroid carcinoma associated with Graves’ disease: results of a large, retrospective, multicenter study

Author

Premoli, P., Tanda, M. L., Piantanida, E., Veronesi, G., Gallo, D., Masiello, E., Rosetti, S., Cusini, C., Boi, F., Bulla, J., Rodia, R., Mariotti, S., Capelli, V., Rotondi, M., Magri, F., Chiovato, L., Rocchi, R., Campopiano, M. C., Elisei, R., Vitti, P., Barbato, F., Pilli, T., Castagna, M. G., Pacini, F., and Bartalena, L.

Published
2020
Full Text
View/download PDF

21. Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life

Author

Cangiano, B, Giusti, E, Premoli, C, Soranna, D, Vitale, G, Grottoli, S, Cambria, V, Mantovani, G, Mungari, R, Maffei, P, Dassie, F, Giampietro, A, Chiloiro, S, Tanda, M, Ippolito, S, Cannavo, S, Ragonese, M, Zambon, A, Persani, L, Fatti, L, Scacchi, M, Cavagnini, F, Ferone, D, Corbetta, S, Bartalena, L, Peccoz, P, Arosio, M, Lania, A, Colao, A, Pivonello, R, Uberti, E, Ghigo, E, Giustina, A, Martino, E, Pontecorvi, A, Sicolo, N, Trimarchi, F, Cangiano B., Giusti E., Premoli C., Soranna D., Vitale G., Grottoli S., Cambria V., Mantovani G., Mungari R., Maffei P., Dassie F., Giampietro A., Chiloiro S., Tanda M. L., Ippolito S., Cannavo S., Ragonese M., Zambon A., Persani L., Fatti L. M., Scacchi M., Cavagnini F., Ferone D., Corbetta S., Bartalena L., Peccoz P. B., Arosio M., Lania A., Colao A., Pivonello R., Uberti E. D., Ghigo E., Giustina A., Martino E., Pontecorvi A., Sicolo N., Trimarchi F., Cangiano, B, Giusti, E, Premoli, C, Soranna, D, Vitale, G, Grottoli, S, Cambria, V, Mantovani, G, Mungari, R, Maffei, P, Dassie, F, Giampietro, A, Chiloiro, S, Tanda, M, Ippolito, S, Cannavo, S, Ragonese, M, Zambon, A, Persani, L, Fatti, L, Scacchi, M, Cavagnini, F, Ferone, D, Corbetta, S, Bartalena, L, Peccoz, P, Arosio, M, Lania, A, Colao, A, Pivonello, R, Uberti, E, Ghigo, E, Giustina, A, Martino, E, Pontecorvi, A, Sicolo, N, Trimarchi, F, Cangiano B., Giusti E., Premoli C., Soranna D., Vitale G., Grottoli S., Cambria V., Mantovani G., Mungari R., Maffei P., Dassie F., Giampietro A., Chiloiro S., Tanda M. L., Ippolito S., Cannavo S., Ragonese M., Zambon A., Persani L., Fatti L. M., Scacchi M., Cavagnini F., Ferone D., Corbetta S., Bartalena L., Peccoz P. B., Arosio M., Lania A., Colao A., Pivonello R., Uberti E. D., Ghigo E., Giustina A., Martino E., Pontecorvi A., Sicolo N., and Trimarchi F.

Abstract

Purpose: Current treatment of acromegaly restores a normal life expectancy in most cases. So, the study of persistent complications affecting patients’ quality of life (QoL) is of paramount importance, especially motor disability and depression. In a large cohort of acromegalic patients we aimed at establishing the prevalence of depression, to look for clinical and sociodemographic factors associated with it, and to investigate the respective roles (and interactions) of depression and arthropathy in influencing QoL. Methods: One hundred and seventy-one acromegalic patients (95 women and 76 men, aged 20–85 years) among those recruited in a cross-sectional Italian multicentric study were investigated. Each patient filled in three validated questionnaires: AcroQoL, WOMAC (measuring articular pain, stiffness and functionality), and AIMS (evaluating articular symptoms and depression). Results: A very high (up to 28%) depression rate was detected in acromegalic subjects. Two patients showing pathological AIMS depression scores, committed suicide during the three years observational period. In our population poor psychological status was significantly associated with female sex. Furthermore, a significant strong correlation was found between AIMS depression score and WOMAC score. Both depression and arthropathy-related motor disability turned out to independently contribute with similar strength to the impairment of QoL. Conclusions: We report a high prevalence of depression in acromegaly, which is associated with female sex and arthropathy. Both depression and arthropathy strongly and independently contribute to the impaired QoL of patients. Our study shows that assessment and monitoring of psychological status is mandatory in acromegaly, also suggesting an inexpensive tool for this assessment.

Published
2022

29. The interplay between thyroid and liver: implications for clinical practice

Author

Piantanida, E., Ippolito, S., Gallo, D., Masiello, E., Premoli, P., Cusini, C., Rosetti, S., Sabatino, J., Segato, S., Trimarchi, F., Bartalena, L., and Tanda, M. L.

Abstract

A complex relationship exists between thyroid and liver in health and disease. Liver plays an essential physiological role in thyroid hormone activation and inactivation, transport, and metabolism. Conversely, thyroid hormones affect activities of hepatocytes and hepatic metabolism. Serum liver enzyme abnormalities observed in hypothyroidism may be related to impaired lipid metabolism, hepatic steatosis or hypothyroidism-induced myopathy. Severe hypothyroidism may have biochemical and clinical features, such as hyperammonemia and ascites, mimicking those of liver failure. Liver function tests are frequently abnormal also in hyperthyroidism, due to oxidative stress, cholestasis, or enhanced osteoblastic activity. Antithyroid drug-associated hepatotoxicity is a rare event, likely related mainly to an idiosyncratic mechanism, ranging from a mild hepatocellular damage to liver failure. Propylthiouracil-induced liver damage is usually more severe than that caused by methimazole. On the other hand, thyroid abnormalities can be found in liver diseases, such as chronic hepatitis C, liver cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma. In particular, autoimmune thyroid diseases are frequently found in patients with hepatitis C virus infection. These patients, especially if thyroid autoimmunity preexists, are at risk of hypothyroidism or, less frequently, thyrotoxicosis, during and after treatment with interpheron-alpha alone or in combination with ribavirin, commonly used before the introduction of new antiviral drugs. The present review summarizes both liver abnormalities related to thyroid disorders and their treatment, and thyroid abnormalities related to liver diseases and their treatment.

Published
2024
Full Text
View/download PDF

30. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy?

Author

Bartalena, L., Veronesi, G., Krassas, G. E., Wiersinga, W. M., Marcocci, C., Marinò, M., Salvi, M., Daumerie, C., Bournaud, C., Stahl, M., Sassi, L., Azzolini, C., Boboridis, K. G., Mourits, M. P., Soeters, M. R., Baldeschi, L., Nardi, M., Currò, N., Boschi, A., Bernard, M., von Arx, G., Perros, P., Kahaly, G. J., and on behalf of the European Group on Graves’ Orbitopathy (EUGOGO)

Published
2017
Full Text
View/download PDF

46. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy

Author

Bartalena, L, primary, Kahaly, G J, additional, Baldeschi, L, additional, Dayan, C M, additional, Eckstein, A, additional, Marcocci, C, additional, Marinò, M, additional, Vaidya, B, additional, Wiersinga, W M, additional, _, _, additional, Ayvaz, Goksun, additional, Konuk, Onur, additional, Ciric, Jasmina, additional, Beleslin, Bijliana, additional, Boschi, Antonella, additional, Cristina Burlacu, Maria, additional, Morris, Dan, additional, Le Moli, Rosario, additional, Marino, Antonio, additional, McKee, Justin, additional, Zammit, Nicola, additional, Führer, Dagmar, additional, Pereni, Ioana, additional, Schittkowski, Michael, additional, Raddatz, Dirk, additional, Lee, Vickie, additional, Meeran, Karim, additional, Abeillon, Juliette, additional, Soui Thcong, Thia, additional, Ponto, Katharina, additional, Muller, Ilaria, additional, Currò, Nicola, additional, Hintschich, Christoph, additional, Gärtner, Roland, additional, Pearce, Simon, additional, Clarke, Lucy, additional, Brix, Thomas, additional, Bechtold, Dorte, additional, Rudovfsky, Gottfried, additional, Fichter, Nicole, additional, Du Pasquier, Laurence, additional, Meney, Julia, additional, Menconi, Francesca, additional, Lanzolla, Giulia, additional, Sundar, Gangadhara, additional, Peiling Yung, Samantha, additional, Boboridis, Kostas, additional, Anagnostis, Panagiotis, additional, Pérez Lopez, Marta, additional, Javier Sanchez, Carlos, additional, Laura Tanda, Maria, additional, Donati, Simone, additional, Papp, Andrea, additional, Li, Shuren, additional, Jablonska, Anna, additional, Miskiewicz, Piotr, additional, Juri Mandic, Jelena, additional, and Baretic, Maja, additional

Published
2021
Full Text
View/download PDF

50. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.

Author

UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'ophtalmologie, UCL - (SLuc) Centre de malformations vasculaires congénitales, Bartalena, L, Kahaly, G J, Baldeschi, L, Dayan, C M, Eckstein, A, Marcocci, C, Marinò, M, Vaidya, B, Wiersinga, W M, EUGOGO †, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'ophtalmologie, UCL - (SLuc) Centre de malformations vasculaires congénitales, Bartalena, L, Kahaly, G J, Baldeschi, L, Dayan, C M, Eckstein, A, Marcocci, C, Marinò, M, Vaidya, B, Wiersinga, W M, and EUGOGO †

Abstract

Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease (GD). Choice of treatment should be based on the assessment of clinical activity and severity of GO. Early referral to specialized centers is fundamental for most patients with GO. Risk factors include smoking, thyroid dysfunction, high serum level of thyrotropin receptor antibodies, radioactive iodine (RAI) treatment, and hypercholesterolemia. In mild and active GO, control of risk factors, local treatments, and selenium (selenium-deficient areas) are usually sufficient; if RAI treatment is selected to manage GD, low-dose oral prednisone prophylaxis is needed, especially if risk factors coexist. For both active moderate-to-severe and sight-threatening GO, antithyroid drugs are preferred when managing Graves' hyperthyroidism. In moderate-to-severe and active GO i.v. glucocorticoids are more effective and better tolerated than oral glucocorticoids. Based on current evidence and efficacy/safety profile, costs and reimbursement, drug availability, long-term effectiveness, and patient choice after extensive counseling, a combination of i.v. methylprednisolone and mycophenolate sodium is recommended as first-line treatment. A cumulative dose of 4.5 g of i.v. methylprednisolone in 12 weekly infusions is the optimal regimen. Alternatively, higher cumulative doses not exceeding 8 g can be used as monotherapy in most severe cases and constant/inconstant diplopia. Second-line treatments for moderate-to-severe and active GO include (a) the second course of i.v. methylprednisolone (7.5 g) subsequent to careful ophthalmic and biochemical evaluation, (b) oral prednisone/prednisolone combined with either cyclosporine or azathioprine; (c) orbital radiotherapy combined with oral or i.v. glucocorticoids, (d) teprotumumab; (e) rituximab and (f) tocilizumab. Sight-threatening GO is treated with several high single doses of i.v. methylprednisolone per week and, if unresponsive, with urgent orbital decom

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results